Eupraxia Pharmaceuticals Inc. (EPRX) News
Track canonical SquawkNews coverage tagged to EPRX, Eupraxia Pharmaceuticals Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Eupraxia Pharmaceuticals Initiated at Outperform by Wedbush
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:49 PM UTC
L
EPRX: Once-yearly dosing and strong safety position the therapy for leadership in EoE and beyond
EoE is a rapidly growing market with significant unmet need, and the therapy’s once-yearly, physician-administered dosing offers strong compliance and commercial advantages. Detailed interim phase II-B data in December w
NEWS | Sep 14, 2026, 07:36 PM UTC
L
EPRX: Once-yearly therapy for EoE targets compliance and durability, with pivotal data due in December
EoE is a rapidly growing market with significant unmet needs, and a once-yearly, physician-administered therapy is positioned to address compliance and durability challenges. Interim Phase IIb data in December will provi
NEWS | Sep 14, 2026, 07:04 PM UTC
L
Eupraxia Pharmaceuticals completes Nasdaq Global Select Market transfer
Eupraxia Pharmaceuticals has completed its transfer to the Nasdaq Global Select Market and announced it will participate in upcoming investor conferences.
EQUITY | Sep 08, 2026, 12:07 PM UTC
L
Eupraxia Pharmaceuticals completes Nasdaq Global Select Market transfer
Eupraxia Pharmaceuticals (EPRX) completes its transfer to the Nasdaq Global Select Market and will participate in upcoming investor conferences.
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Eupraxia Pharmaceuticals reports new RESOLVE Phase 1b/2a symptom response data
Eupraxia Pharmaceuticals (EPRX) reports symptom response data from its ongoing Phase 1b/2a RESOLVE trial, including new data on odynophagia in eosinophilic esophagitis patients.
EQUITY | Aug 13, 2026, 12:10 PM UTC
L
Eupraxia Pharmaceuticals Q2 EPS In Line
Eupraxia Pharmaceuticals reports Q2 EPS of $(0.23), meeting estimates
EARNINGS | Aug 11, 2026, 09:32 PM UTC
L
EPRX Reports Second Quarter 2026 Financial Results
Eupraxia Pharmaceuticals reports second quarter 2026 financial results
EARNINGS | Aug 11, 2026, 09:21 PM UTC
M
EPRX: Oppenheimer Initiates
Oppenheimer initiates coverage on Eupraxia Pharmaceuticals with an Outperform rating and a price target of $17
EQUITY | Jun 26, 2026, 01:12 PM UTC
M
BDC: BUY @ Citi
Citi initiates BDC with a BUY rating, among other top initiations
EQUITY | Jun 26, 2026, 11:17 AM UTC